Unlock instant, AI-driven research and patent intelligence for your innovation.

Oral formulation for twice-daily administration

An oral medicine, secondary technology, applied in the direction of drug combination, drug delivery, pharmaceutical formulation, etc., can solve the problems of forgetting to take, unable to get full effect, unable to treat pigmentation disease and other problems

Active Publication Date: 2012-11-07
SS PHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, the current commercially available preparation divides the maximum daily dose of 240 mg of L-cysteine ​​into three times, and each time takes 80 mg of L-cysteine, which must be taken three times a day.
A preparation that must be taken continuously for three months, and the number of times of taking a day is large, is likely to cause forgetting to take it for a patient who lives in a normal social life, and thus cannot maximize the L-half. Therapeutic effect of cystine on hyperpigmentation caused by age spots, freckles, sunburn, macules, etc.
On the other hand, preparations that are taken less frequently than three times a day, because the daily dose of L-cysteine ​​is smaller when compared with 80 mg of L-cysteine ​​taken three times a day, so the patient's Depending on the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Dragee formulations:

[0027] Weigh 960 grams of L-cysteine, 1200 grams of ascorbic acid, 96 grams of calcium pantothenate, 688 grams of crystalline cellulose, 128 grams of partially α-starch, 80 grams of hydroxypropyl cellulose, 16 grams of light anhydrous silicic acid, 16 grams of magnesium stearate and 16 grams of talc, these are thoroughly mixed. Subsequently, this mixture was made into tablets by a usual method so that the weight of each tablet was 200 mg to obtain plain tablets. Subsequently, this tablet was put into the coating chamber, and the coating liquid (ethanol containing 5% by weight of hydroxypropylmethylcellulose: purified water = 1:1) was used to increase the weight by 10 mg per tablet. coating. Furthermore, using a coating solution (containing 2% by weight of talc, 2% by weight of titanium oxide, 3% by weight of calcium carbonate, 1% by weight of gum arabic powder, and 60% by weight of refined white sugar), the weight was increased by 100 mg per tab...

Embodiment 2

[0037] Powder formulation (1):

[0038] 200 grams of L-cysteine, 250 grams of ascorbic acid, 20 grams of calcium pantothenate, 180 grams of cornstarch, 340 grams of lactose, and 10 grams of magnesium stearate were uniformly mixed. The obtained mixed powder is subpackaged into 600 mg per package, containing 120 mg of L-cysteine, 150 mg of ascorbic acid, 12 mg of calcium pantothenate in one package, and is the present invention in the form of subpackaged powder Powder formulation for twice-a-day consumption.

Embodiment 3

[0040] Powder formulation (2):

[0041] 150 grams of L-cysteine, 250 grams of ascorbic acid, 20 grams of calcium pantothenate, 180 grams of cornstarch, 390 grams of lactose, and 10 grams of magnesium stearate were uniformly mixed. The obtained mixed powder is subpackaged into 600 mg per package, containing 90 mg of L-cysteine, 150 mg of ascorbic acid, 12 mg of calcium pantothenate in one package, and is the present invention in the form of subpackaged powder. Powder formulation for twice-a-day consumption.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an oral drug which should be taken two times one day, wherein it is characterized in that: it comprises: L-cysteamine or its salt, and ascorbic acid or its salt; one-time drug supply of L- cysteamine is 90-150mg; and it can treat color sink disease caused by ephelis.

Description

technical field [0001] The present invention relates to an oral pharmaceutical preparation containing L-cysteine ​​or its salt, ascorbic acid or its salt, which can exert maximum effect on pigmentation caused by age spots, freckles, sunburn, macules, etc. treatment effect. Background technique [0002] L-cysteine ​​(2-amino-3-mercaptopropionic acid; 2-Amino-3-mercaptopropionic acid), which contains sulfur (S) in the molecule, has a hydrogen sulfide (SH) group in the living body One of the sulfur-containing amino acids that donate to the body. This L-cysteine ​​is considered to exhibit the biochemical action of maintaining or activating the activity of various enzymes through the SH group contained in the molecule. In addition, L-cysteine ​​is used for the treatment of various skin diseases or the treatment of leukopenia caused by radiation therapy through normalization of skin metabolism, antiallergic effect, detoxification, etc. [0003] In the prior art, L-cysteine ​​pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/375A61K31/525A61K31/714A61K31/51A61K31/4415A61K31/455A61K31/4188A61K36/8994A61K9/00A61P17/00A61K31/198
CPCA63B9/00A63B69/0048A63B2009/002A63B2009/006
Inventor 冈田实小贯洋一仓住敏明大泷宗志
Owner SS PHARMA CO LTD